HOME >> BIOLOGY >> NEWS
New gene therapy shows promise for hemophiliacs

MINNEAPOLIS / ST. PAUL -- University of Minnesota researchers have demonstrated that it may be possible to treat hemophilia A through the use of human blood outgrowth endothelial cells, or BOECs, as a vehicle for gene therapy. Lead researcher Robert Hebbel, M.D., the George Clark Professor and vice chair for research, department of medicine, reports that the use of BOECs has "resulted in sustained and therapeutic levels of factor 8 (FVIII) in mice and may comprise an effective therapeutic strategy for use in gene therapy for humans with hemophilia A." The results of this gene therapy, published in the January 15 issue of Blood, may pave the way for testing the therapy in humans.

Hemophilia A is an inherited blood disorder that affects one in 5,000 males and results in spontaneous bleeding due to the lack of coagulation factor 8 (FVIII) in the blood. Because hemophilia is such a severe disease, and because it is caused by absence of a replaceable blood protein, there has been a high level of interest in developing a gene therapy approach for its treatment. While there are currently some ongoing Phase I clinical studies of gene therapy for humans for hemophilia B (a related disorder that affects a different coagulation factor), development of gene therapy for hemophilia A has lagged behind. Current clinical therapy generally calls for the replacement of factor VIII after the patient has had some trouble.

The ex vivo process devised by Hebbel utilizes BOECs as carriers for gene therapy. The process begins with a blood sample taken from the patient as a source for autologous BOECs. (This use of autologous cells eliminates the concern for immunological compatibility or disease-tainted blood sources). The BOECs are separated from the blood and cultured in the lab and then transfected with a nonviral plasmid vector carrying the gene for human coagulation factor VIII. After allowing them to further expand, those stably transfected BOECs are then given
'"/>

Contact: Deane Morrison
morri029@umn.edu
612-624-2346
University of Minnesota
18-Jan-2002


Page: 1 2

Related biology news :

1. Targeted therapy knocks out pediatric brain cancer in mice
2. New anti-inflammatory strategy for cancer therapy identified by UCSD researchers
3. Columbia research to examine gene influence on severity of peridontal disease, therapy response
4. Case for IBD combination therapy comes from research at Baylor, MIT and Hebrew University
5. The search for a kinder, gentler chemotherapy
6. Embryonic stem cell therapy shows steady benefits in rebuilding infarcted heart
7. Retroviral gene therapy? ASLV, HIV, and MLV show distinct target site preferences
8. Gene changes linked to increased eye pressure may have implications for glaucoma therapy
9. Jefferson Lab detector technology aids development of cystic fibrosis therapy
10. Stroking up cellular therapy
11. Smart gene therapy protects against damage from heart attack

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: New gene therapy shows promise for hemophiliacs

(Date:8/24/2015)... 24, 2015 The consulting company Frost ... biometrics manufacturer DERMALOG and its customized solutions and products for ... Company of the Year Award". DERMALOG is particularly successful with ...   -Cross reference: Picture is available at AP ... On Thursday evening, in South Africa,s ...
(Date:8/19/2015)... N.Y. , Aug. 19, 2015  VOXX ... that it has entered into a Definitive Agreement ... property, of iris authentication market leader EyeLock through ... VOXX will have a controlling interest in the ... subject to completion of due diligence.  Expanding on ...
(Date:8/12/2015)... Florida , August 12, 2015 ... pace of mobile payment innovation and advanced biometrics technology ... replace the way consumers rely on using their credit ... with reinventing the future for payment services led by ... NXTD ), :  Google, Inc. (NASDAQ: GOOG ...
Breaking Biology News(10 mins):Frost & Sullivan Honors DERMALOG with Biometrics Prize for Achievements in Africa 2Frost & Sullivan Honors DERMALOG with Biometrics Prize for Achievements in Africa 3VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 2VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 3VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 4VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 5Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 2Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 3Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 4Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 5Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 6
(Date:9/2/2015)... Israel , September 2, 2015 ... the intent of the National Institute of Allergy and Infectious ... (NIH) within the Department of Health and Human Services (HHS), ... in the United States in the ... universal flu vaccine candidate, Multimeric-001 (M-001), as a primer vaccine, ...
(Date:9/2/2015)... ... September 02, 2015 , ... Advancing ... high-risk surgeries. From vital sign monitoring in ICU to 3D skull printing analysis ... to make real-time clinical decisions with simultaneous access to high precision medical images ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... of their entire waste to energy process and continue to contribute to the ... Upgrade , Temarry’s Waste to Energy process has been operating at their Mexico ...
(Date:9/2/2015)... ... 2015 , ... Genedata, a leading provider of advanced software ... ® version 13.0 at ELRIG Drug Discovery 2015. This latest version of the ... new capabilities. Screener now supports High Throughput Flow Cytometry (HT-Flow) and Drug Metabolism ...
Breaking Biology Technology:BiondVax Announces Intent to Launch a Phase 2 Trial in the United States in Collaboration with the U.S. National Institutes of Health 2BiondVax Announces Intent to Launch a Phase 2 Trial in the United States in Collaboration with the U.S. National Institutes of Health 3Surgical Workstation Powered by 6th Gen. Intel® Core™ Skylake Processors 2Surgical Workstation Powered by 6th Gen. Intel® Core™ Skylake Processors 3Temarry Recycling’s New $100,000 Waste to Energy Renovation 2New Genedata Screener 13.0 with Support for High Throughput Flow Cytometry and DMPK Unveiled at ELRIG 2New Genedata Screener 13.0 with Support for High Throughput Flow Cytometry and DMPK Unveiled at ELRIG 3New Genedata Screener 13.0 with Support for High Throughput Flow Cytometry and DMPK Unveiled at ELRIG 4
Cached News: